Paclitaxel-Coated Balloons and Stents - Increased mortality or statistical anomaly?

Dr. Darren Schneider and Dr. Joseph Mills recently participated in the Vascular Leaders Forum: Drug Elution in Peripheral Artery Disease (PAD): A Critical Analysis from a Multispecialty Consortium on March 1-2, 2019 and take time tell us what they heard and how it has impacted their practice.

Darren Schneider, MD (@VascularMD) is Chief of Vascular and Endovascular Surgery at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.  He completed his training and was on faculty at the University of California, San Francisco and has extensive experience in minimally invasive vascular procedures and research interests in the design and development of endovascular devices for the treatment of aortic aneurysm and peripheral arterial diseases. Disclosures: None.

Joseph Mills, MD (@jmills1955) is Professor and Chief of the Division of Vascular Surgery & Endovascular Therapy at the Baylor College of Medicine.  He has held numerous leadership positions in vascular surgery, is co-editor for Rutherford’s Vascular Surgery and is most well known for his work in developing the WIfI wound criteria for critical limb ischemia. Disclosures: None

(04:15) Risk of Death Following Application of Paclitaxel‐Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

(11:30) FDA UPDATE: Treatment of Peripheral Arterial Disease with Paclitaxel-Coated Balloons and Paclitaxel-Eluting Stents Potentially Associated with Increased Mortality - Letter to Health Care Providers

(12:30) Coronary stents - SPIRIT trial